"Seventeen drug companies, including some of the world’s largest, are flouting a 30-year-old federal program that supports hospitals serving patients with low incomes and those who live in rural communities. Both the Trump and Biden administrations have deemed these actions unlawful. But these drugmakers continue to ignore the law,...
"This spring, I find myself embracing the change of season and reflecting on the challenges of seasons past. For two years, we intensive-care professionals have cared for critically ill COVID-19 patients with ravaged lungs who clung for life on ventilators. We witnessed tragic and heartbreaking...
"President Biden’s call during his State of the Union address for Congress to pass legislation to control drug prices provides a good opportunity to note a law that already is on the books that helps curb drugmakers’ price hikes. As lawmakers prepare to debate the...
"A late 2021 survey of hospitals participating in the 340B drug pricing program suggests pharma industry leaders’ recent restrictions on drug discounts are costing safety net hospitals hundreds of thousands to millions of dollars in savings. 340B Health, an industry group representing these hospitals, said critical...
"The main lobbying association for drug makers, the Pharmaceutical Research and Manufacturers of America, spent a record $28.9 million on lobbying last year as it pushed back on legislation meant to control the price of medicine. The trade group asked lawmakers instead to create an out-of-pocket...
"The hospital industry pushed back on the findings, the latest salvo in an ongoing battle over the program, which provider trade groups like the American Hospital Association and America's Essential Hospitals argue is essential to preserving the financial stability of safety net facilities and their...
The 340B drug pricing program may discourage drug manufacturers from raising prices and instead may have the effect of reducing list prices for certain drugs. That’s according to a new study published in the Journal of the American Medical Association (JAMA). Study authors Sean Dickson of West Health and Ian...
"Rural hospitals are facing a crisis, as many close or struggle to stay on top of rising expenses. But a new study shows that savings from the 340B drug pricing program are helping rural hospitals pay for other programs. The report from 340Bhealth.org comes from a survey of over 1,300...
"At a recent hearing of the Senate Finance Committee, Chairman Sen. Chuck Grassley (R-Iowa) warned the seven assembled drug company executives not to point fingers: “It’s time for solutions,” he said. They didn’t listen. Instead, they blamed everything from pharmacy benefit managers to Medicaid to the...
"Hospitals participating in the 340B drug discount program saved an average of $11.8 million per year, according to a new report from 340B Health. For its annual report, released in June, the alliance of hospitals and health systems participating in the 340B drug-pricing program, last year...
